DGX Quest Diagnostics, Inc.
Quest Diagnostics, Inc. (DGX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 97% planned / 3% discretionary
Largest single sale: $7.9M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| PREVOZNIK MICHAEL E 3 fills | SVP & General Counsel | Sell 10b5-1 | 22,677 | $243.11 | $5.5M | 44,224 −33.9% of holding | |
| DELANEY MARK E | SVP & Chief Commercial Officer | Sell 10b5-1 | 1,600 | $235.18 | $376.3K | 10,335 −13.4% of holding | |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Sell 10b5-1 | 8,147 | $200.00 | $1.6M | 13,510 −37.6% of holding | |
| Davis J. E. | CEO and President | Sell 10b5-1 | 10,000 | $194.14 | $1.9M | 132,423 −7% of holding | |
| Doherty Catherine T. | EVP, Regional Businesses | Sell 10b5-1 | 5,558 | $206.21 | $1.1M | 67,122 −7.6% of holding | |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Sell 10b5-1 | 3,878 | $206.21 | $799.7K | 37,557 −9.4% of holding | |
| Plewman Patrick | SVP for Diagnostic Services | Sell 10b5-1 | 2,855 | $206.21 | $588.7K | 15,198 −15.8% of holding | |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | Sell | 2,628 | $204.86 | $538.4K | 13,441 −16.4% of holding | |
| Doherty Catherine T. | EVP, Regional Businesses | Sell 10b5-1 | 632 | $207.73 | $131.3K | 67,122 −0.9% of holding | |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Sell 10b5-1 | 526 | $207.73 | $109.3K | 37,557 −1.4% of holding | |
| Plewman Patrick | SVP for Diagnostic Services | Sell 10b5-1 | 410 | $207.73 | $85.2K | 15,198 −2.6% of holding | |
| Davis J. E. | CEO and President | Sell 10b5-1 | 10,000 | $212.52 | $2.1M | 117,185 −7.9% of holding | |
| Doherty Catherine T. | EVP, Regional Businesses | Sell 10b5-1 | 1,433 | $204.83 | $293.5K | 68,402 −2.1% of holding | |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Sell 10b5-1 | 1,111 | $204.83 | $227.6K | 38,371 −2.8% of holding | |
| Plewman Patrick | SVP for Diagnostic Services | Sell 10b5-1 | 958 | $204.83 | $196.2K | 15,838 −5.7% of holding | |
| Doherty Catherine T. 5 fills | EVP, Regional Businesses | Sell 10b5-1 | 26,165 | $206.15 | $5.4M | 83,660 −23.8% of holding | |
| Plewman Patrick | SVP for Diagnostic Services | Sell 10b5-1 | 5,662 | $204.00 | $1.2M | 15,381 −26.9% of holding | |
| Davis J. E. 3 fills | CEO and President | Sell 10b5-1 | 55,093 | $192.22 | $10.6M | 166,231 −24.9% of holding | |
| Gregg Vicky B | Director | Sell | 1,250 | $191.76 | $239.7K | 17,037 −6.8% of holding | |
| DELANEY MARK E | SVP & Chief Commercial Officer | Sell 10b5-1 | 7,946 | $187.35 | $1.5M | 7,530 −51.3% of holding | |
| PFEIFFER GARY M | Director | Sell | 1,482 | $182.40 | $270.3K | 29,431 −4.8% of holding | |
| PREVOZNIK MICHAEL E 2 fills | SVP & General Counsel | Sell 10b5-1 | 227 | $188.13 | $42.7K | 38,261 −0.6% of holding | |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Sell 10b5-1 | 175 | $187.02 | $32.7K | 38,117 −0.5% of holding | |
| PREVOZNIK MICHAEL E | SVP & General Counsel | Sell 10b5-1 | 28,288 | $187.12 | $5.3M | 38,117 −42.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.